To quantify and compare the treatment effects on three surrogate end points, progression-free survival (PFS), time to progression (TTP), and tumor response rate (TR) vs. overall survival (OS) based on a meta-analysis of randomized controlled trials (RCTs) of drug interventions in advanced colorectal cancer (aCRC).
Using the end-point progression scoring system allowed reasonable comparison of these two chemicals, if desired, by linking the preneoplastic score of 4 for resmethrin, to the neoplastic score of 5 for metaldehyde, along the continuum of end-point progression.
The incidence of liver pathology between rats and mice was comparable when we grouped end-point progression scores.
Figure 3B presents the distribution of end-point progression scores for rat and mouse, liver and kidney.
End-point progression scoring reduced the possible chemical classifications to a single ordinal score (i.e., scores 0 5) for each target organ.
The end point progression scheme we presented (Martin et al. 2009a) included aggregation of prolifera tive, preneoplastic, and neoplastic lesions for the development of predictive signatures from in vitro data coming from the ToxCast research program (U.S. EPA 2008a).
The lowest risk was found to be when treatment was initiated within 1 year of MS onset, which significantly reduced the risk of a 1-point progression in EDSS score, compared with treatment initiated > 1 year from MS onset.
The results on the primary end point, progression-free survival (PFS), were published while this manuscript was being finalised.
Secondary end points included progression free survival, overall survival, and toxicity.
If no radiographs were obtained at one of these two points, the progression rate was calculated based on available scores.
